neuroendocrine tumors C80 C17 C25.9
Conditions
Interventions
Group 1: Therapy companion imaging is performed in patients with neuroendocrine tumors treated by Lutetium-177 DOTATATE. Organ doses were calculated using image data. Beside, the standard protocol def
Sponsors
Universitätsklinikum Magdeburg
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: - Indication for Lutetium-177-DOTATATE therapy - by minimum two successfully performed therapy cycles - age > 18 years - normal renal function - no contraindication for the second examinations (e.g. claustrophobia, poor general condition)
Exclusion criteria
Exclusion criteria: Missing compliance to the additional examinations
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Comparison in detection rate of focal lesions by two different SPECT/CT-systems for (1.) scintigraphy and (2.) SPECT/CT in Lutetium-177-DOTATATE therapy | — |
Secondary
| Measure | Time frame |
|---|---|
| - Comparison of reader's confidence in image quality in whole body scintigraphy for both detector technologies - Comparison of reader's confidence in image quality and assignment to morphologic structures for SPECT(NaJ)/CT and SPECT(CZT)/CT -Comparison of uptake/nuclide accumulation in defined target regions (e.g. tumor, kidney) | — |
Countries
Germany
Contacts
Public ContactAnja Zinke
Klinik für Radiologie und Nuklearmedizin
Outcome results
None listed